NURS 6630 FINAL EXAM (2024) WALDEN UNIVERSITY – COMPREHENSIVE QUESTIONS
AND ANSWERS | VERIFIED AND WELLDETAILED ANSWERS | DETAILED EXPLANATIONS AND
RATIONALES | COMPLETE EXAM PREPARATION STUDY GUIDE | PRACTICE QUESTIONS |
LATEST EXAM UPDATE
CORE DOMAINS
• Foundations of neuroscience and psychopharmacology
• Pharmacokinetics, pharmacodynamics, and medication safety
• Antidepressant pharmacotherapy
• Antipsychotic medications and management of psychosis
• Mood stabilizers and treatment of bipolar disorders
• Anxiolytic, sedative, and sleep-related pharmacotherapy
• Pharmacologic treatment of substance use and related disorders
• Psychopharmacology across the lifespan
• Medication monitoring, adverse effects, adherence, and patient education
• Ethical, legal, cultural, and patient-centered prescribing
INTRODUCTION
This comprehensive assessment is designed to reinforce the knowledge and clinical reasoning
expected in NURS 6630, Psychopharmacologic Approaches to Treatment of Psychopathology.
The material emphasizes foundational neuroscience, mechanisms of action, evidence-based
medication selection, efficacy and adverse-effect monitoring, and safe psychopharmacologic
management. Questions progress from foundational concepts to application and clinical
decision-making involving common psychiatric conditions. Effective preparation requires
more than memorizing medication names: learners should understand receptor activity,
pharmacokinetics, therapeutic monitoring, drug interactions, safety considerations, patient
factors, and appropriate follow-up. The questions are structured to provide practice with
examination-style distinctions and practical prescribing situations.
SECTION ONE: QUESTIONS 1–100
Question 1. Which neurotransmitter is most directly associated with the regulation of mood,
anxiety, sleep, and appetite?
A. Dopamine
B. Serotonin
C. Glutamate
D. Acetylcholine
Correct Answer: B. Serotonin
Explanation: Serotonin, or 5-hydroxytryptamine (5-HT), participates in mood, anxiety, sleep,
appetite, and several other physiologic processes. Many antidepressants exert their
therapeutic effects by modifying serotonergic neurotransmission.
,Question 2. Which neurotransmitter is the primary inhibitory neurotransmitter in the central
nervous system?
A. GABA
B. Glutamate
C. Dopamine
D. Norepinephrine
Correct Answer: A. GABA
Explanation: Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter
in the CNS. Increased GABAergic activity generally decreases neuronal excitability, which is
central to the effects of benzodiazepines and several other CNS-active medications.
Question 3. Which neurotransmitter is the major excitatory neurotransmitter in the central
nervous system?
A. Serotonin
B. GABA
C. Glutamate
D. Glycine
Correct Answer: C. Glutamate
Explanation: Glutamate is the major excitatory neurotransmitter in the CNS. It contributes to
learning, memory, synaptic plasticity, and neuronal signaling and is implicated in several
psychiatric and neurologic disorders.
Question 4. Which receptor type is generally responsible for the fastest neurotransmitter-
mediated responses?
A. Nuclear receptors
B. G-protein-coupled receptors
C. Ligand-gated ion channels
D. Intracellular steroid receptors
Correct Answer: C. Ligand-gated ion channels
Explanation: Ligand-gated ion channels directly alter ion flow across the neuronal membrane
after ligand binding. Because they act directly on ion channels, their effects are generally
faster than those mediated through second-messenger systems.
Question 5. A medication has a high affinity for a receptor but produces little or no activation
of that receptor. How should this medication be classified?
A. Full agonist
B. Partial agonist
, C. Antagonist
D. Inverse agonist only
Correct Answer: C. Antagonist
Explanation: An antagonist can bind to a receptor with affinity but does not activate it. By
occupying the receptor, it can prevent an agonist from producing its usual effect.
Question 6. What is the primary distinction between a full agonist and a partial agonist?
A. A partial agonist cannot bind to receptors
B. A full agonist produces greater intrinsic activity when occupying the same receptor
C. A full agonist always has a longer half-life
D. A partial agonist is always clinically ineffective
Correct Answer: B. A full agonist produces greater intrinsic activity when occupying the same
receptor
Explanation: Full agonists can produce maximal receptor activation, whereas partial agonists
have lower intrinsic activity even when they occupy receptors extensively.
Question 7. Which pharmacokinetic process describes the movement of a medication from
the site of administration into systemic circulation?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Correct Answer: A. Absorption
Explanation: Absorption is the movement of a drug from its administration site into the
systemic circulation. Route of administration, formulation, gastrointestinal function, and
first-pass metabolism can influence this process.
Question 8. Which organ is primarily responsible for hepatic drug metabolism?
A. Heart
B. Liver
C. Spleen
D. Pancreas
Correct Answer: B. Liver
Explanation: The liver is the principal site of drug metabolism. Hepatic enzymes, particularly
cytochrome P450 enzymes, can transform medications into metabolites that may be active,
inactive, or toxic.
Question 9. What does the term “half-life” describe?
AND ANSWERS | VERIFIED AND WELLDETAILED ANSWERS | DETAILED EXPLANATIONS AND
RATIONALES | COMPLETE EXAM PREPARATION STUDY GUIDE | PRACTICE QUESTIONS |
LATEST EXAM UPDATE
CORE DOMAINS
• Foundations of neuroscience and psychopharmacology
• Pharmacokinetics, pharmacodynamics, and medication safety
• Antidepressant pharmacotherapy
• Antipsychotic medications and management of psychosis
• Mood stabilizers and treatment of bipolar disorders
• Anxiolytic, sedative, and sleep-related pharmacotherapy
• Pharmacologic treatment of substance use and related disorders
• Psychopharmacology across the lifespan
• Medication monitoring, adverse effects, adherence, and patient education
• Ethical, legal, cultural, and patient-centered prescribing
INTRODUCTION
This comprehensive assessment is designed to reinforce the knowledge and clinical reasoning
expected in NURS 6630, Psychopharmacologic Approaches to Treatment of Psychopathology.
The material emphasizes foundational neuroscience, mechanisms of action, evidence-based
medication selection, efficacy and adverse-effect monitoring, and safe psychopharmacologic
management. Questions progress from foundational concepts to application and clinical
decision-making involving common psychiatric conditions. Effective preparation requires
more than memorizing medication names: learners should understand receptor activity,
pharmacokinetics, therapeutic monitoring, drug interactions, safety considerations, patient
factors, and appropriate follow-up. The questions are structured to provide practice with
examination-style distinctions and practical prescribing situations.
SECTION ONE: QUESTIONS 1–100
Question 1. Which neurotransmitter is most directly associated with the regulation of mood,
anxiety, sleep, and appetite?
A. Dopamine
B. Serotonin
C. Glutamate
D. Acetylcholine
Correct Answer: B. Serotonin
Explanation: Serotonin, or 5-hydroxytryptamine (5-HT), participates in mood, anxiety, sleep,
appetite, and several other physiologic processes. Many antidepressants exert their
therapeutic effects by modifying serotonergic neurotransmission.
,Question 2. Which neurotransmitter is the primary inhibitory neurotransmitter in the central
nervous system?
A. GABA
B. Glutamate
C. Dopamine
D. Norepinephrine
Correct Answer: A. GABA
Explanation: Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter
in the CNS. Increased GABAergic activity generally decreases neuronal excitability, which is
central to the effects of benzodiazepines and several other CNS-active medications.
Question 3. Which neurotransmitter is the major excitatory neurotransmitter in the central
nervous system?
A. Serotonin
B. GABA
C. Glutamate
D. Glycine
Correct Answer: C. Glutamate
Explanation: Glutamate is the major excitatory neurotransmitter in the CNS. It contributes to
learning, memory, synaptic plasticity, and neuronal signaling and is implicated in several
psychiatric and neurologic disorders.
Question 4. Which receptor type is generally responsible for the fastest neurotransmitter-
mediated responses?
A. Nuclear receptors
B. G-protein-coupled receptors
C. Ligand-gated ion channels
D. Intracellular steroid receptors
Correct Answer: C. Ligand-gated ion channels
Explanation: Ligand-gated ion channels directly alter ion flow across the neuronal membrane
after ligand binding. Because they act directly on ion channels, their effects are generally
faster than those mediated through second-messenger systems.
Question 5. A medication has a high affinity for a receptor but produces little or no activation
of that receptor. How should this medication be classified?
A. Full agonist
B. Partial agonist
, C. Antagonist
D. Inverse agonist only
Correct Answer: C. Antagonist
Explanation: An antagonist can bind to a receptor with affinity but does not activate it. By
occupying the receptor, it can prevent an agonist from producing its usual effect.
Question 6. What is the primary distinction between a full agonist and a partial agonist?
A. A partial agonist cannot bind to receptors
B. A full agonist produces greater intrinsic activity when occupying the same receptor
C. A full agonist always has a longer half-life
D. A partial agonist is always clinically ineffective
Correct Answer: B. A full agonist produces greater intrinsic activity when occupying the same
receptor
Explanation: Full agonists can produce maximal receptor activation, whereas partial agonists
have lower intrinsic activity even when they occupy receptors extensively.
Question 7. Which pharmacokinetic process describes the movement of a medication from
the site of administration into systemic circulation?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Correct Answer: A. Absorption
Explanation: Absorption is the movement of a drug from its administration site into the
systemic circulation. Route of administration, formulation, gastrointestinal function, and
first-pass metabolism can influence this process.
Question 8. Which organ is primarily responsible for hepatic drug metabolism?
A. Heart
B. Liver
C. Spleen
D. Pancreas
Correct Answer: B. Liver
Explanation: The liver is the principal site of drug metabolism. Hepatic enzymes, particularly
cytochrome P450 enzymes, can transform medications into metabolites that may be active,
inactive, or toxic.
Question 9. What does the term “half-life” describe?
